C07D 213/28
Radicals substituted by singly-bound oxygen or sulphur atoms
C07D213/28 (Radicals substituted by singly-bound oxygen or sulphur atoms) appears on 2,113 US grants and 1,470 published applications in this corpus.
Search patents in C07D- Granted patents
- 2,113
- Published applications
- 1,470
- Assignees
- 840
- Inventors
- 5,600
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 35 | 0 |
| 1977 | 45 | 0 |
| 1978 | 36 | 0 |
| 1979 | 27 | 0 |
| 1980 | 36 | 0 |
| 1981 | 46 | 0 |
| 1982 | 36 | 0 |
| 1983 | 28 | 0 |
| 1984 | 23 | 0 |
| 1985 | 33 | 0 |
| 1986 | 26 | 0 |
| 1987 | 23 | 0 |
| 1988 | 34 | 0 |
| 1989 | 38 | 0 |
| 1990 | 43 | 0 |
| 1991 | 39 | 0 |
| 1992 | 41 | 0 |
| 1993 | 45 | 0 |
| 1994 | 33 | 0 |
| 1995 | 38 | 0 |
| 1996 | 39 | 0 |
| 1997 | 57 | 0 |
| 1998 | 73 | 0 |
| 1999 | 46 | 0 |
| 2000 | 44 | 0 |
| 2001 | 56 | 6 |
| 2002 | 47 | 59 |
| 2003 | 60 | 82 |
| 2004 | 39 | 107 |
| 2005 | 49 | 82 |
| 2006 | 55 | 65 |
| 2007 | 48 | 69 |
| 2008 | 44 | 63 |
| 2009 | 50 | 84 |
| 2010 | 44 | 84 |
| 2011 | 55 | 69 |
| 2012 | 57 | 56 |
| 2013 | 69 | 62 |
| 2014 | 61 | 79 |
| 2015 | 49 | 43 |
| 2016 | 47 | 76 |
| 2017 | 57 | 62 |
| 2018 | 40 | 31 |
| 2019 | 49 | 48 |
| 2020 | 32 | 47 |
| 2021 | 39 | 38 |
| 2022 | 22 | 38 |
| 2023 | 22 | 32 |
| 2024 | 15 | 39 |
| 2025 | 26 | 33 |
| 2026 | 17 | 16 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Phenolic acid lipid based cationic lipids29 Sep 2026US 12,747,198 B2Translate Bio, Inc.
- Compounds for the treatment of bacterial infections and potentiation of antibiotics8 Sep 2026US 12,728,105 B2Georgia State University Research Foundation, Inc.
- Cinnamamide derivatives and use thereof1 Sep 2026US 12,721,842 B2Korea Research Institute of Bioscience and Biotechnology
- Corrosion-resistant articles and methods for making such18 Aug 2026US 12,709,687 B2Saudi Arabian Oil Company
- Inhibitors of notch signaling pathway and use thereof in treatment of cancers16 Jun 2026US 12,655,141 B2Cellestia Biotech AG
- Inhibitors of Notch Signaling Pathway and Use Thereof in Treatment of Cancers1 Oct 2026US 2026/0297082 A1Cellestia Biotech AG
- Highly water soluble schiff base prodrugs of benzaldehyde allosteric modulators3 Sep 2026US 2026/0256752 A1Illexcor Holdings, LLC
- Novel sulfanone derivative or pharmaceutically acceptable salt thereof, and use thereof27 Aug 2026US 2026/0248772 A1Korea Institute of Science and Technology
- N-Myristoyltransferase Inhibitors And Methods Of Use30 Jul 2026US 2026/0217686 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Spiro-containing platinum compound and organic light-emitting device30 Jul 2026US 2026/0217750 A1Guangdong Aglaia Optoelectronic Materials Co., Ltd
Most cited
By later US patents
- Electroluminescent iridium compounds with fluorinated phenylpyridines, phenylpyrimidines, and phenylquinolines and devices made with such compounds232US 6,670,645 B2E. I. Du Pont de Nemours and Company · 2003
- Thiazolidinedione derivatives, useful as antidiabetic agents228US 4,687,777 ATakeda Chemical Industries, Ltd. · 1987
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998